{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:58:23Z","timestamp":1692619103675},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00347-020-01250-y","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T09:09:22Z","timestamp":1604480962000},"page":"68-77","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity"],"prefix":"10.1007","volume":"118","author":[{"name":"German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"German Retina Society e.\u202fV. (Retinologische Gesellschaft e.\u202fV., RG)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Professional Association of German Ophthalmologists (Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV., BVA)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"1250_CR1","doi-asserted-by":"publisher","first-page":"F21","DOI":"10.1136\/archdischild-2013-303799","volume":"99","author":"J Aitken","year":"2014","unstructured":"Aitken\u00a0J, Williams\u00a0FLR (2014) A systematic review of thyroid dysfunction in preterm neonates exposed to topical iodine. Arch Dis Child Fetal Neonatal Ed 99:F21\u2013F28. https:\/\/doi.org\/10.1136\/archdischild-2013-303799","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1250_CR2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1012-1999","author":"M Andrassi-Darida","year":"2019","unstructured":"Andrassi-Darida\u00a0M, Mais\u00a0C, Stieger\u00a0K, Lorenz\u00a0B (2019) Fluorescence angiography-assisted management of recurrences in aggressive posterior retinopathy of prematurity (APROP) after Intravitreal monotherapy with 0.312\u202fmg Bevacizumab. Klin Monbl Augenheilkd. https:\/\/doi.org\/10.1055\/a-1012-1999 (online ahead of print)","journal-title":"Klin Monbl Augenheilkd"},{"key":"1250_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery\u00a0RL, Castellarin\u00a0AA, Steinle\u00a0NC et\u00a0al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636\u20131641. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305252","journal-title":"Br J Ophthalmol"},{"key":"1250_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative G (2003) Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthalmol 121:1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"1250_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jaapos.2004.12.018","volume":"9","author":"E Garcia-Valenzuela","year":"2005","unstructured":"Garcia-Valenzuela\u00a0E, Kaufman\u00a0LM (2005) High myopia associated with retinopathy of prematurity is primarily lenticular. J\u00a0AAPOS 9:121\u2013128. https:\/\/doi.org\/10.1016\/j.jaapos.2004.12.018","journal-title":"J AAPOS"},{"key":"1250_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck\u00a0MM, Chuang\u00a0AZ, Clark\u00a0WL et\u00a0al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a\u00a0randomized clinical trial. JAMA Ophthalmol 132:1327\u20131333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772","journal-title":"JAMA Ophthalmol"},{"key":"1250_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00006982-199703000-00009","volume":"17","author":"RJ Hairston","year":"1997","unstructured":"Hairston\u00a0RJ, Maguire\u00a0AM, Vitale\u00a0S, Green\u00a0WR (1997) Morphometric analysis of pars plana development in humans. Retina 17:135\u2013138. https:\/\/doi.org\/10.1097\/00006982-199703000-00009","journal-title":"Retina"},{"key":"1250_CR8","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu\u00a0J, Blair\u00a0MP, Shapiro\u00a0MJ et\u00a0al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006. https:\/\/doi.org\/10.1001\/archophthalmol.2012.592","journal-title":"Arch Ophthalmol"},{"key":"1250_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"C-Y Huang","year":"2018","unstructured":"Huang\u00a0C\u2011Y, Lien\u00a0R, Wang\u00a0N\u2011K et al (2018) Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 256:479\u2013487. https:\/\/doi.org\/10.1007\/s00417-017-3878-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1250_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1055\/s-2005-858231","volume":"222","author":"GB Jaissle","year":"2005","unstructured":"Jaissle\u00a0GB, Szurman\u00a0P, Bartz-Schmidt\u00a0KU et al (2005) Recommendation for the implementation of intravitreal injections\u2014statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monbl Augenheilkd 222:390\u2013395. https:\/\/doi.org\/10.1055\/s-2005-858231","journal-title":"Klin Monbl Augenheilkd"},{"key":"1250_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong\u00a0L, Bhatt\u00a0AR, Demny\u00a0AB et al (2015) Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF\u20111 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56:956\u2013961. https:\/\/doi.org\/10.1167\/iovs.14-15842","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1250_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00347-012-2618-8","volume":"109","author":"TU Krohne","year":"2012","unstructured":"Krohne\u00a0TU, Aisenbrey\u00a0S, Holz\u00a0FG (2012) Current therapeutic options in retinopathy of prematurity. Ophthalmologe 109:1189\u20131197. https:\/\/doi.org\/10.1007\/s00347-012-2618-8","journal-title":"Ophthalmologe"},{"key":"1250_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00347-018-0675-3","volume":"115","author":"PP Larsen","year":"2018","unstructured":"Larsen\u00a0PP, Br\u00fcnder\u00a0M\u2011C, Petrak\u00a0M et al (2018) Screening for retinopathy of prematurity: Trends over the past 5 years in two German university hospitals. Ophthalmologe 115:469\u2013475. https:\/\/doi.org\/10.1007\/s00347-018-0675-3","journal-title":"Ophthalmologe"},{"key":"1250_CR14","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien\u00a0R, Yu\u00a0M\u2011H, Hsu\u00a0K\u2011H et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and Bevacizumab treatment. PLoS ONE 11:e148019. https:\/\/doi.org\/10.1371\/journal.pone.0148019","journal-title":"PLoS ONE"},{"key":"1250_CR15","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner\u00a0HA, Geloneck\u00a0MM, Chuang\u00a0AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal Bevacizumab monotherapy. Ophthalmology 123:1845\u20131855. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"key":"1250_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner\u00a0HA, Kennedy\u00a0KA, Chuang\u00a0AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N\u00a0Engl J Med 364:603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"1250_CR17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","author":"J Morin","year":"2016","unstructured":"Morin\u00a0J, Luu\u00a0TM, Superstein\u00a0R et\u00a0al (2016) Neurodevelopmental outcomes following Bevacizumab injections for retinopathy of prematurity. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2015-3218","journal-title":"Pediatrics"},{"key":"1250_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/bjo.2009.162156","volume":"94","author":"CK Patel","year":"2010","unstructured":"Patel\u00a0CK, Walker\u00a0NJ, Kam\u00a0JK (2010) A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Br J Ophthalmol 94:1107\u20131109. https:\/\/doi.org\/10.1136\/bjo.2009.162156","journal-title":"Br J Ophthalmol"},{"key":"1250_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991\u2013999. https:\/\/doi.org\/10.1001\/archopht.123.7.991","journal-title":"Arch Ophthalmol"},{"key":"1250_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/s0161-6420(92)31968-2","volume":"99","author":"GE Quinn","year":"1992","unstructured":"Quinn\u00a0GE, Dobson\u00a0V, Repka\u00a0MX et\u00a0al (1992) Development of myopia in infants with birth weights less than 1251 grams. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 99:329\u2013340. https:\/\/doi.org\/10.1016\/s0161-6420(92)31968-2","journal-title":"Ophthalmology"},{"key":"1250_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0161-6420(00)00527-3","volume":"108","author":"GE Quinn","year":"2001","unstructured":"Quinn\u00a0GE, Dobson\u00a0V, Siatkowski\u00a0R et\u00a0al (2001) Does cryotherapy affect refractive error? Results from treated versus control eyes in the cryotherapy for retinopathy of prematurity trial. Ophthalmology 108:343\u2013347. https:\/\/doi.org\/10.1016\/s0161-6420(00)00527-3","journal-title":"Ophthalmology"},{"key":"1250_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl\u00a0A, Krohne\u00a0TU, Eter\u00a0N et\u00a0al (2018) Comparing alternative Ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 172:278\u2013286. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr"},{"key":"1250_CR23","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl\u00a0A, Lepore\u00a0D, Fielder\u00a0A et al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394:1551\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"1250_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.0334","author":"DK Wallace","year":"2020","unstructured":"Wallace\u00a0DK, Kraker\u00a0RT, Freedman\u00a0SF et al (2020) Short-term outcomes after very low-dose intravitreous Bevacizumab for retinopathy of prematurity. JAMA Ophthalmol. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.0334","journal-title":"JAMA Ophthalmol"},{"key":"1250_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00347-018-0701-5","volume":"115","author":"JM Walz","year":"2018","unstructured":"Walz\u00a0JM, Bemme\u00a0S, Reichl\u00a0S et al (2018) Treated cases of retinopathy of prematurity in Germany: 5\u2011year data from the Retina.net ROP Registry. Ophthalmologe 115:476\u2013488. https:\/\/doi.org\/10.1007\/s00347-018-0701-5","journal-title":"Ophthalmologe"},{"key":"1250_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00103-007-0337-0","volume":"50","author":"Kommission f\u00fcr Krankenhaushygiene und Infektionspr\u00e4vention beim Robert Koch-Institut","year":"2007","unstructured":"Kommission f\u00fcr Krankenhaushygiene und Infektionspr\u00e4vention beim Robert Koch-Institut (2007) Bundesgesundheitsbl 50:1265\u20131303. https:\/\/doi.org\/10.1007\/s00103-007-0337-0","journal-title":"Bundesgesundheitsbl"},{"key":"1250_CR27","unstructured":"Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Berufsverband der Augen\u00e4rzte Deutschlands (BVA), Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin (DGKJ), Berufsverband der Kinder- und Jugend\u00e4rzte e.\u202fV. (BVKJ), Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c e.\u202fV. und Gesellschaft f\u00fcr Neonatologie und P\u00e4diatrische Intensivmedizin (GNPI) (2020) Augen\u00e4rztliche Screening-Untersuchung bei Fr\u00fchgeborenen: Gemeinsame Empfehlung von Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Berufsverband der Augen\u00e4rzte Deutschlands (BVA), Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin (DGKJ), Berufsverband der Kinder- und Jugend\u00e4rzte e.\u202fV. (BVKJ), Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c e.\u202fV. und Gesellschaft f\u00fcr Neonatologie und P\u00e4diatrische Intensivmedizin (GNPI). https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/024-010.html. Zugegriffen: 17.07.2020"},{"key":"1250_CR28","unstructured":"Grundel\u00a0M, Br\u00fcnder\u00a0MC, Stahl\u00a0A, Grundel\u00a0B. Therapie der Fr\u00fchgeborenenretinopathie. In Vorbereitung."}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01250-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-020-01250-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01250-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T11:51:31Z","timestamp":1611229891000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-020-01250-y"}},"subtitle":["Released: 18\u00a0May 2020"],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":28,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s00347-020-01250-y","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"4 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"See Table\u00a0InternalRef removed in the Appendix.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}